SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tandem Diabetes Care, Inc.
TNDM 113.37+0.7%3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Labrador11/2/2018 5:32:34 AM
   of 11
 
Tandem Diabetes Care®, Inc. ( TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018." data-reactid="12" style="margin: 0px 0px 1em; color: rgb(38, 40, 42); font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; background-color: rgb(255, 255, 255);">andem Diabetes Care®, Inc. ( TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.

Third Quarter 2018 Results

In comparing the third quarter of 2018 to the same period of 2017:

Pump shipments increased 118 percent to 8,434 pumps from 3,868 pumpsSales increased 71 percent to $46.3 million from $27.0 millionOperating margin improved to negative 34 percent from negative 49 percent“We delivered a record-setting quarter in terms of robust sales, improving gross margin and modest use of cash,” said Kim Blickenstaff, president and chief executive officer. “We’ll be working to build upon this momentum by continuing to scale our business into a leading global diabetes management organization, while advancing our product pipeline and furthering our mission to improve the lives of people with diabetes.”

Total pump shipments of 8,434 included 1,055 pumps for the launch of international operations to select geographies outside the United States, which commenced in August 2018. This resulted in international sales of $2.5 million, or 5 percent of total sales of $46.3 million in the third quarter of 2018.

Gross profit for the third quarter of 2018 increased 84 percent to $21.8 million, compared to $11.9 million for the same period of 2017. Gross margin was 47 percent for the quarter ended September 30, 2018, compared to 44 percent in the same period of 2017. This included a non-cash charge of $0.8 million for stock-based compensation in the third quarter of 2018, compared to $0.3 million for the comparable period of 2017.

For the third quarter of 2018, operating expenses totaled $37.5 million, compared to $25.0 million for the same period of 2017. Operating expenses included a non-cash charge for stock-based compensation of $8.8 million, compared to stock-based compensation of $2.1 million for the comparable period of 2017. Operating loss for the third quarter of 2018 was $15.7 million, compared to $13.2 million for the same period of 2017.

Net loss for the third quarter of 2018 was $34.2 million, which included a $12.3 million non-cash charge for the change in fair value of the Series A warrants issued in the Company’s October 2017 financing, as well as a $5.3 million charge associated with the full repayment of the Company’s term loan agreement in August 2018. This compares to a net loss of $16.0 million for the third quarter of 2017.

Cash Balance and Liquidity

As of September 30, 2018, the Company had $113.6 million in cash, cash equivalents and short-term investments. This balance reflects the net impact from $108.9 million in net proceeds related to the Company’s equity financing completed in August 2018 that was then used for the full repayment of the Company’s term loan agreement. The balance of the outstanding debt was approximately $82.7 million, plus approximately $5.0 million in associated financing fees that became due upon repayment. Excluding these financing transactions, the Company’s net use of cash in the third quarter of 2018 was $4.5 million compared to $19.2 million in the same period of 2017.

2018 Annual Guidance

For the year ending December 31, 2018, the Company is increasing its financial guidance as follows:

Sales are estimated to be in the range of $160 million to $165 million, which represents an annual sales growth of 49 percent to 53 percent compared to 2017Operating margin is estimated to be in the range of negative 37 percent to negative 32 percent, which includes:Approximately $20.0 million in non-cash, stock-based compensation expenseApproximately $7.0 million to $8.0 million of depreciation and amortizationConference Call

The Company will hold a conference call and simultaneous webcast today at 5:30pm Eastern Time (2:30pm Pacific Time). The link to the webcast and information regarding the use of non-GAAP financial measures will be available by accessing the Investor Center of the Tandem Diabetes Care website at cts.businesswire.com, and will be archived for 30 days. To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code "1782389".

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ Insulin Pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark, and t:slim X2 and Basal-IQ are trademarks of Tandem Diabetes Care, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext